Leukemia

Children and young adults with acute lymphoblastic leukemia who received higher doses of tisagenlecleucel achieved significantly longer OS and RFS, according to study results presented at TCT Meetings Digital Experience.

The FDA granted breakthrough therapy designation to asciminib for treatment of certain patients with chronic myeloid leukemia.

Younger Black patients who received tisagenlecleucel for acute lymphoblastic leukemia had significantly poorer outcomes than those of other races or ethnicities, according to results presented at TCT Meetings Digital Experience.

The FDA cleared an investigational new drug application for KITE-222, a chimeric antigen receptor T-cell therapy for adults with relapsed or refractory acute myeloid leukemia, according to the agent’s manufacturer.

Patients undergoing bone marrow biopsy would respond favorably to interventions intended to improve their experience, according to study results presented at TCT Meetings Digital Experience.

Patients who developed AKI during hospitalization with hematologic malignancy experienced a significantly increased risk for kidney function decline and chronic kidney disease in the following year.

Acalabrutinib conferred a similar PFS benefit as ibrutinib for adults with previously treated high-risk chronic lymphocytic leukemia, according to topline results of a randomized phase 3 trial.

The FDA cleared an investigational new drug application for VOR33, an engineered stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse, according to the agent’s manufacturer.

Roswell Park Comprehensive Cancer Center announced the hiring or promotion of several people across clinical, administrative and research departments.

The FDA granted breakthrough therapy designation to avapritinib for treatment of moderate to severe indolent systemic mastocytosis, according to the agent’s manufacturer.